Novartis received approval from the FDA for Ilaris (canakinumab) for the treatment of children and adults with cryopyrin-associated periodic syndrome (CAPS), which includes a number of rare but life-long auto-inflammatory disorders with debilitating symptoms and limited treatment options. The drug was granted priority review based on its potential to meet an important clinical need for CAPS patients. Ilaris is the first approved treatment for patients as young as four years old suffering from...